Short Interest in TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Drops By 98.8%

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) saw a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 3,800 shares, a decrease of 98.8% from the January 15th total of 318,300 shares. Based on an average daily volume of 104,400 shares, the short-interest ratio is presently 0.0 days.

TC Biopharm Trading Up 10.4 %

Shares of NASDAQ TCBP traded up $0.34 during trading on Wednesday, reaching $3.56. The company had a trading volume of 204,502 shares, compared to its average volume of 66,589. TC Biopharm has a 12-month low of $3.18 and a 12-month high of $523.20. The business’s 50-day moving average is $8.33 and its 200 day moving average is $44.71.

Wall Street Analyst Weigh In

Separately, HC Wainwright decreased their price target on shares of TC Biopharm from $112.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, December 6th.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.